Group 1 - The A-shares and Hong Kong stocks collectively declined on May 30, while the Hang Seng-Hushen Hong Kong Innovative Drug Selected 50 Index rose against the trend [1] - The Tianhong Innovative Drug ETF (517380) increased by 1.77%, ranking among the top fifteen ETFs in the market, with significant gains from constituent stocks such as Ruizhi Pharmaceutical and Yangguang Nuohuo [1] - The Tianhong Innovative Drug ETF has accumulated a rise of over 6.5% from May 6 to May 29 [1] Group 2 - The Biopharmaceutical ETF (159859) closely tracks the National Index of Biopharmaceuticals and is the largest product in its category, also offering connecting funds [2] - On May 29, the National Medical Products Administration issued approvals for 11 new drugs, with five coming from innovative companies on the Sci-Tech Innovation Board, covering various treatment areas [2] - The 2025 ASCO conference is expected to showcase significant data from domestic innovative drugs, with 71 original research results from Chinese pharmaceutical companies selected for presentation [2] Group 3 - CITIC Securities predicts a clear trend of performance and valuation recovery in the healthcare industry in the second half of 2025, with a focus on innovation-driven and internationalization strategies [3] - The optimization of centralized procurement policies is expected to positively impact market sentiment and lead to a recovery in the valuation of many sub-sectors in the pharmaceutical industry [3]
创新药ETF天弘（517380）逆市涨超1.7%，暂居全市场ETF涨幅前十五，机构：创新药市场情绪与板块估值将进入正向修复通道
2 1 Shi Ji Jing Ji Bao Dao·2025-05-30 03:35